NOT that I remotely suggesting it statistically significant at only 15 patients (or being critical of MSB before the usual recriminations start) but MSB's recent GvHD trial reported:
"Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only approved agent in adults".
CYP reported "Patients treated with CYP-001 had a two-year overall survival rate of 60% (9/15 patients)" by comparison in its small phase 1 trial.
Ann: Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $53.16K | 331.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 58274 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 4405 | 2 |
View Market Depth
| Last trade - 14.11pm 25/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |